Target intelligence / Profile preview

Glutathione-dependent formaldehyde dehydrogenase (FDH (also commonly called FALDH or ADH3))

Target
FDH (also commonly called FALDH or ADH3)
Molecular classification
Enzyme, Oxidoreductase, Medium-chain dehydrogenase/reductase (MDR) family
01

Overview

Glutathione-dependent formaldehyde dehydrogenase is a zinc-containing enzyme essential for formaldehyde detoxification in most eukaryotes, including humans, where it is identical to class III alcohol dehydrogenase (ADH3)[2][4][5]. It catalyzes the NAD+-dependent oxidation of S-hydroxymethylglutathione (formed from the spontaneous reaction of glutathione with formaldehyde) to S-formylglutathione, thus neutralizing toxic formaldehyde[2]. Uniquely, this enzyme is also a potent S-nitrosoglutathione (GSNO) reductase, influencing NO signaling and cellular redox states[7][8]. The enzyme operates via a zinc-assisted mechanism, with critical roles described for Glu-67 and Arg-368 in catalysis and cofactor binding[1][3][5]. Expression and activity of this enzyme affect glutathione homeostasis and have been implicated in the regulation of cell proliferation, redox biology, stress responses, and potentially in disease contexts such as cancer, neurodegeneration, and inflammation[7][8]. In plants and animals alike, the enzyme’s broad substrate specificity and evolutionary conservation indicate its fundamental metabolic importance[4].

Other names
Formaldehyde dehydrogenaseS-nitrosoglutathione reductaseGSNO reductaseClass III alcohol dehydrogenase (ADH3)Glutathione-dependent alcohol dehydrogenaseS-(hydroxymethyl)glutathione dehydrogenase
02

Mechanism of action

Catalytic oxidation of S-hydroxymethylglutathione, formed from formaldehyde and glutathione, using NAD+ as a cofactor, producing S-formylglutathione[2]. Reduces S-nitrosoglutathione (GSNO), regulating NO signaling[7][8]. Mechanistic sequence involves a zinc-dependent catalytic site[1][3][5].

03

Biological functions

Formaldehyde detoxificationOxidation of S-hydroxymethylglutathione to S-formylglutathioneNitric oxide (NO) signaling via reduction of S-nitrosoglutathione (GSNO)Regulation of glutathione homeostasisParticipation in cell protection against aldehydic stress
04

Disease associations

CancerNeurodegenerative diseaseInflammationOther (roles in plant defense and environmental detoxification)
05

Safety considerations

Potential safety or therapeutic challenges could arise from off-target effects on glutathione and NO metabolism, impacting oxidative stress responses and cancer cell redox balance, but no clinical toxicities are established for targeting this enzyme specifically; see caveats below.
06

Interacting drugs

None explicitly named as approved drugs currently target this enzyme clinically, but experimental inhibitors and modulators include dodecanoic acid (as a structural inhibitor in studies)[5], and pyrazole (not inhibitory to this enzyme class)[2]. See caveats below.
07

Biomarkers

Levels of S-formylglutathione/S-hydroxymethylglutathione (indirectly reflect enzyme activity)GSNO levels (for NO signaling/oxidative stress)Not an established clinical biomarker but studied in metabolic and stress-response contexts

Beyond the preview

Go deeper on Glutathione-dependent formaldehyde dehydrogenase (FDH (also commonly called FALDH or ADH3)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutathione-dependent formaldehyde dehydrogenase (FDH (also commonly called FALDH or ADH3)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call